Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NMRA-M4R by Neumora Therapeutics for Schizophrenia: Likelihood of Approval
NMRA-M4R is under clinical development by Neumora Therapeutics and currently in Phase I for Schizophrenia. According to GlobalData, Phase I...
Data Insights
Risk adjusted net present value: What is the current valuation of Neumora Therapeutics's NMRA-M4R?
NMRA-M4R is commercialized by Neumora Therapeutics, with a leading Phase I program in Schizophrenia. According to Globaldata, it is involved...